Advertisement

Topics

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

02:21 EDT 19 Oct 2016 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
COPENHAGEN, Denmark, Oct. 19, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 6,315,789 American Depositary Shares ("ADSs"), each o...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs"

Quick Search
Advertisement
 

Relevant Topic

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...